Coloplast A/S (OTCMKTS:CLPBY) Short Interest Update

Coloplast A/S (OTCMKTS:CLPBYGet Rating) saw a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 19,100 shares, a growth of 365.9% from the April 15th total of 4,100 shares. Based on an average trading volume of 220,500 shares, the short-interest ratio is currently 0.1 days.

A number of equities research analysts have recently commented on CLPBY shares. DNB Markets upgraded shares of Coloplast A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, January 26th. JPMorgan Chase & Co. lowered their price objective on shares of Coloplast A/S from 1,014.00 to 980.00 and set a “neutral” rating for the company in a research note on Tuesday. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. According to, the stock has a consensus rating of “Hold” and a consensus price target of $1,038.00.

Shares of CLPBY stock opened at $12.10 on Thursday. The stock has a fifty day moving average price of $14.43 and a 200 day moving average price of $15.44. The stock has a market cap of $26.14 billion, a PE ratio of 40.33 and a beta of 0.28. Coloplast A/S has a 1 year low of $11.84 and a 1 year high of $18.90. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.90 and a current ratio of 1.29.

About Coloplast A/S (Get Rating)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates in three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand.

Read More

Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with's FREE daily email newsletter.